Supermax Corporation Berhad (SPMXF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Supermax Corporation Berhad (SPMXF) trades at $0.15 with AI Score 54/100 (Grade B). Supermax Corporation Berhad is a Malaysian investment holding company primarily engaged in the manufacturing, distribution, and marketing of medical gloves and contact lenses. Market cap: $458.59M, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for SPMXF: SPMXF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SPMXF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
SPMXF: 2/6 perspectives are bullish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Supermax Corporation Berhad (SPMXF) Healthcare & Pipeline Overview
Supermax Corporation Berhad, a Malaysian-based investment holding company, specializes in manufacturing and distributing medical gloves, contact lenses, and personal protective equipment. Operating globally across 165 countries, it leverages brands like Supermax and Aurelia to serve healthcare sectors, while also engaging in biomass energy generation and property holding activities.
What Is the Investment Thesis for SPMXF?
Supermax Corporation Berhad's investment profile is anchored by its established position in the global medical glove and contact lens markets, supported by a broad distribution network spanning approximately 165 countries. The company's core value proposition stems from its manufacturing capabilities for natural rubber and nitrile latex gloves, essential products with consistent demand in healthcare, laboratory, and pharmaceutical sectors. While the company currently reports a profit margin of -30.2%, its gross margin of 37.8% suggests underlying operational efficiency in its core manufacturing activities, indicating potential for profitability improvement through cost management or revenue growth. Key growth catalysts include potential recovery in global demand for medical consumables post-pandemic normalization, expansion into new geographical markets, and diversification within its healthcare product portfolio, such as contact lenses and other medical devices. The company's engagement in biomass energy generation also presents a long-term opportunity for sustainable operations and potential cost savings. However, investors must consider the negative profit margin and the company's OTC "Other" tier classification, which implies lower disclosure standards and potential liquidity challenges. The beta of 0.16 suggests relatively low volatility compared to the broader market, which might appeal to investors seeking stability, but this must be weighed against the operational and market-specific risks inherent in its business model and OTC listing.
Based on FMP financials and quantitative analysis
SPMXF Key Highlights
- Market capitalization stands at $0.46 billion, reflecting its current valuation in the market.
- Reported a gross margin of 37.8%, indicating the profitability of its core manufacturing and distribution operations before operating expenses.
- Currently experiencing a negative profit margin of -30.2%, highlighting challenges in achieving overall profitability.
- Exports products to approximately 165 countries, demonstrating a significant international market presence and distribution network.
- Operates with a Beta of 0.16, suggesting lower historical volatility relative to the broader market.
Who Are SPMXF's Competitors?
SPMXF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| NYXH Nyxoah S.A. | $1.75 | +1.74% | $69.31M | 69 |
| KMTS Kestra Medical Technologies, Ltd. | $27.70 | +2.67% | $1.62B | 67 |
| ZTEK Zentek Ltd. | $0.46 | +2.88% | $49.90M | 63 |
| OMIC Singular Genomics Systems, Inc. | $20.01 | +0.00% | $50.77M | 61 |
| AZTA Azenta, Inc. | $25.86 | +0.08% | $1.19B | 54 |
| NNCSF Nanosonics Limited | $2.07 | -18.82% | $618.75M | 54 |
| ATR AptarGroup, Inc. | $126.69 | -0.23% | $8.09B | 54 |
| NVCR Novocure | $17.70 | +2.92% | $2.05B | 55 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SPMXF's Key Strengths?
- Extensive global distribution network covering approximately 165 countries.
- Diversified product portfolio including medical gloves, contact lenses, and PPE under established brands (Supermax, Aurelia, Maxter).
- Involvement in biomass energy generation, potentially leading to operational cost savings and sustainability benefits.
- Long operational history since 1987, indicating experience and market presence.
What Are SPMXF's Weaknesses?
- Reported negative profit margin of -30.2%, indicating current unprofitability.
- OTC "Other" tier classification, suggesting lower disclosure standards and potential liquidity issues.
- Reliance on the medical glove market, which can be subject to demand fluctuations and intense competition.
- Unknown disclosure status on the OTC market, posing transparency challenges for investors.
What Could Drive SPMXF Stock Higher?
- Global demand for medical consumables, including gloves and PPE, driven by persistent healthcare needs and hygiene standards.
- Strategic diversification into contact lenses and other medical devices, potentially opening new revenue streams.
- Potential for improved profitability through operational efficiencies or a recovery in the medical glove market pricing.
- Expansion of its international distribution network to further penetrate emerging markets.
What Are the Key Risks for SPMXF?
- Negative return on equity (-5.8%) — the business is not currently generating profit on shareholder capital.
- Negative profit margin of -30.2% indicates current operational unprofitability, posing a significant financial risk.
- Exposure to volatile raw material costs (e.g., natural rubber, nitrile latex) which can impact manufacturing margins.
- Intense competition within the global medical glove and PPE market, potentially leading to price erosion and market share loss.
- Risks associated with its OTC "Other" tier listing, including limited disclosure, lower liquidity, and potential difficulty in valuation.
- Fluctuations in global healthcare spending or changes in regulatory requirements in key export markets.
What Are the Growth Opportunities for SPMXF?
- Expansion in Emerging Markets: Supermax's existing export network to approximately 165 countries provides a strong foundation for deeper penetration into emerging markets in Asia, the Middle East, and the South Pacific. These regions often exhibit growing healthcare infrastructure and increasing awareness of hygiene standards, driving demand for medical consumables like gloves and PPE. By leveraging its established distribution channels and brand recognition (Supermax, Aurelia, Maxter), the company can target underserved areas, potentially increasing market share and sales volumes. The global medical glove market is projected to continue growing, with significant contributions from these developing economies, offering a substantial addressable market for Supermax to capitalize on in the coming years.
- Diversification into Advanced Medical Devices: While currently focused on gloves and contact lenses, Supermax's involvement in "marketing and distribution of healthcare products and medical devices" suggests a strategic pathway for growth. Expanding its portfolio to include more specialized or technologically advanced medical devices could open new revenue streams and reduce reliance on the cyclical glove market. This could involve partnerships, acquisitions, or in-house development of products catering to specific medical specialties, such as diagnostic equipment or surgical instruments. The global medical device market is a multi-trillion-dollar industry with consistent innovation and demand, offering significant long-term growth potential for a company with established healthcare distribution capabilities.
- Increased Focus on Contact Lens Market: Supermax's engagement in the contact lens market represents a distinct growth opportunity. The global contact lens market is driven by increasing rates of myopia, presbyopia, and aesthetic preferences, alongside technological advancements in lens materials and comfort. By investing further in research and development for new contact lens products, improving manufacturing efficiencies, and expanding its distribution channels specifically for optical retailers and ophthalmologists, Supermax could capture a larger share of this growing market. This segment offers a different demand profile compared to medical gloves, providing a valuable diversification of revenue and potentially higher margin opportunities.
- Leveraging Biomass Energy Generation: Supermax's involvement in "generation of biomass energy" presents a dual growth opportunity. Firstly, it can lead to significant cost savings in energy consumption for its manufacturing facilities, improving operational efficiency and gross margins over time. Secondly, if scaled, it could potentially become a source of revenue through the sale of excess energy or carbon credits. As global industries increasingly prioritize sustainability, a strong commitment to renewable energy sources can also enhance the company's brand reputation and appeal to environmentally conscious investors and customers. This initiative aligns with global trends towards green manufacturing and could provide a competitive advantage in the long run.
- Strategic Partnerships and Acquisitions: To accelerate growth and market penetration, Supermax could pursue strategic partnerships or targeted acquisitions. Collaborating with local distributors in new regions could enhance market access and reduce entry barriers. Acquiring smaller, specialized medical device or contact lens manufacturers could provide access to new technologies, intellectual property, or customer bases, thereby expanding its product offerings and market share more rapidly. Such inorganic growth strategies, if executed prudently, could significantly bolster Supermax's competitive position and accelerate its expansion into higher-value segments of the healthcare market, particularly in regions like the US and EU where it already exports.
What Opportunities Does SPMXF Have?
- Expansion into new or deeper penetration of existing emerging markets for healthcare products.
- Further diversification within the medical device and healthcare product distribution segments.
- Increased demand for contact lenses driven by demographic trends and technological advancements.
- Leveraging biomass energy initiatives for enhanced sustainability and potential cost efficiencies.
What Threats Does SPMXF Face?
- Intense competition from other global medical glove and PPE manufacturers.
- Volatile raw material prices (natural rubber, nitrile latex) impacting production costs and margins.
- Regulatory changes or stricter compliance requirements in key export markets.
- Economic downturns impacting healthcare spending and demand for non-essential medical items.
What Are SPMXF's Competitive Advantages?
- Established Global Distribution Network: Exports to approximately 165 countries, providing significant market reach and brand recognition for its Supermax, Aurelia, and Maxter brands.
- Diversified Product Portfolio: Offers a range of natural rubber and nitrile latex gloves, contact lenses, and other PPE, catering to broad healthcare needs.
- Manufacturing Scale and Efficiency: As a long-standing manufacturer since 1987, the company likely benefits from economies of scale and established production processes in medical glove manufacturing.
- Brand Recognition: Its Supermax, Aurelia, and Maxter brands are utilized by laboratories, pharmacists, hospitals, doctors, and surgeons, indicating a degree of market acceptance and trust.
What Does SPMXF Do?
Founded in 1987 and headquartered in Sungai Buloh, Malaysia, Supermax Corporation Berhad has evolved into a significant player in the global healthcare supply chain. Initially established as an investment holding company, its core operations revolve around the manufacturing, distribution, and marketing of medical gloves and contact lenses. The company's product portfolio is extensive, featuring various types of natural rubber and nitrile latex gloves, which are critical components in medical and laboratory settings for infection control and personal protection. Beyond gloves, Supermax also produces and distributes a range of personal protective equipment (PPE), catering to the broader needs of healthcare professionals and institutions. Supermax operates under a multi-brand strategy, with prominent brands such as Supermax, Aurelia, and Maxter recognized in the market. These brands are distributed to a diverse customer base that includes laboratories, pharmacists, hospitals, doctors, and surgeons, highlighting the company's deep penetration into the professional healthcare segment. The company's business model extends beyond manufacturing to include the trading, importing, and distribution of latex gloves, enhancing its supply chain capabilities and market reach. Geographically, Supermax Corporation Berhad boasts a robust international presence, exporting its products to approximately 165 countries worldwide. Key export markets include the United States, the European Union, the Middle East, Asia, and the South Pacific countries, underscoring its global operational footprint and ability to meet diverse international demands. In addition to its primary healthcare product lines, Supermax has diversified its operations to include other strategic areas. This diversification encompasses the generation of biomass energy, reflecting a commitment to sustainable practices and potentially providing an alternative revenue stream. Furthermore, the company is involved in the marketing and distribution of other healthcare products and medical devices, broadening its offerings within the healthcare sector. Property holding activities also form part of its investment portfolio, indicating a broader strategy for asset management and value creation. With 1624 employees, Supermax Corporation Berhad maintains a substantial operational scale, supporting its manufacturing, distribution, and administrative functions across its various business segments.
What Products and Services Does SPMXF Offer?
- Manufactures natural rubber and nitrile latex medical gloves.
- Produces and distributes contact lenses.
- Offers a range of personal protective equipment (PPE).
- Engages in the trading, importing, and distribution of latex gloves.
- Generates biomass energy as part of its operations.
- Markets and distributes other healthcare products and medical devices.
- Holds property as part of its investment activities.
- Exports products globally to approximately 165 countries.
How Does SPMXF Make Money?
- Manufacturing and Sales: Primarily generates revenue through the production and direct sale of medical gloves, contact lenses, and personal protective equipment under its own brands (Supermax, Aurelia, Maxter).
- Global Distribution: Utilizes an extensive international network to export products to approximately 165 countries, serving diverse healthcare markets worldwide.
- Trading and Importing: Supplements its manufacturing by trading, importing, and distributing latex gloves, optimizing supply chain efficiency and market responsiveness.
- Diversified Investments: Engages in property holding and biomass energy generation, providing additional revenue streams and operational efficiencies beyond its core healthcare product lines.
What Industry Does SPMXF Operate In?
Supermax Corporation Berhad operates within the highly competitive and essential Medical - Instruments & Supplies industry, specifically focusing on medical gloves and contact lenses. This sector is characterized by continuous demand driven by global healthcare needs, hygiene standards, and an aging population. The company's positioning as a manufacturer and global distributor of natural rubber and nitrile latex gloves places it directly in a market segment that experienced significant demand surges during the recent pandemic, followed by a period of normalization and oversupply. Current market trends include a focus on sustainable manufacturing practices, advanced material science for improved glove performance, and stringent regulatory compliance. Supermax competes with other large-scale glove manufacturers globally, differentiating itself through its multi-brand strategy (Supermax, Aurelia, Maxter) and extensive international export network across 165 countries. Its diversification into contact lenses, personal protective equipment, and biomass energy generation also positions it to capture opportunities in related healthcare segments and sustainable operations.
Who Are SPMXF's Key Customers?
- Laboratories requiring sterile and protective gloves for research and testing.
- Pharmacists and pharmacies for over-the-counter medical supplies.
- Hospitals and clinics for a wide array of medical gloves, PPE, and other devices for patient care and surgical procedures.
- Doctors and surgeons utilizing specialized gloves and equipment in their practices.
- International distributors and healthcare providers in 165 countries.
Company Profile
Supermax Corporation Berhad operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Sungai Buloh, MY. The company is led by CEO Chee Keong Tan. SPMXF has traded publicly since 2013.
F-Score 4/9Financial Health
Supermax Corporation Berhad's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 4.53 places it in the safe zone, indicating low near-term bankruptcy risk.
ROE -6%Key Financial Metrics
Return on equity for Supermax Corporation Berhad stands at -5.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -5.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -21.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.95 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -27.1%, the inverse of the P/E and a quick read on earnings relative to price.
SPMXF Valuation & Market Position
With a $458.59M market cap, Supermax Corporation Berhad sits in the small-cap segment of the market. Relative to its peer group, SPMXF's quantitative score of 54/100 is roughly in line with the peer average of 63/100.
FY2026 estForward Outlook
Wall Street analysts project Supermax Corporation Berhad revenue of about $838.4M for fiscal 2026, with EPS near $-0.03. The estimate reflects 5 contributing analysts.
SPMXF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Extensive global distribution network covering approximately 165 countries.
- Diversified product portfolio including medical gloves, contact lenses, and PPE under established brands (Supermax, Aurelia, Maxter).
- Involvement in biomass energy generation, potentially leading to operational cost savings and sustainability benefits.
- Long operational history since 1987, indicating experience and market presence.
Bear Case
- Reported negative profit margin of -30.2%, indicating current unprofitability.
- OTC "Other" tier classification, suggesting lower disclosure standards and potential liquidity issues.
- Reliance on the medical glove market, which can be subject to demand fluctuations and intense competition.
- Unknown disclosure status on the OTC market, posing transparency challenges for investors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
SPMXF Latest News
No recent news available for SPMXF.
SPMXF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SPMXF.
Price Targets
Wall Street price target analysis for SPMXF.
SPMXF MoonshotScore
What does this score mean?
The MoonshotScore rates SPMXF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Chee Keong Tan
Unknown
Information regarding Chee Keong Tan's specific career history, educational background, and previous roles prior to his current position at Supermax Corporation Berhad is not provided in the available source data. His professional journey and credentials that led to his leadership role are currently unknown, preventing a detailed overview of his formative experiences within the industry or other sectors.
Track Record: Specific details regarding Chee Keong Tan's key achievements, strategic decisions, or significant company milestones directly attributable to his leadership at Supermax Corporation Berhad are not available in the provided source materials. His track record in terms of company performance, strategic initiatives, or major operational shifts under his direction remains undisclosed.
SPMXF OTC Market Information
Supermax Corporation Berhad trades on the OTC market under the "OTC Other" tier. This classification typically applies to companies that do not meet the disclosure requirements for OTCQX or OTCQB, or choose not to be categorized in those tiers. Unlike major exchanges such as NYSE or NASDAQ, which have stringent listing standards for financial reporting, corporate governance, and minimum share prices, the OTC Other tier has minimal to no ongoing disclosure requirements with the SEC. This means companies in this tier may not regularly provide audited financial statements or other material information, leading to reduced transparency for investors compared to exchange-listed or higher-tier OTC stocks.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Public Information: The "Unknown" disclosure status means investors may not have access to timely or comprehensive financial and operational data, hindering informed decision-making.
- Lower Liquidity: OTC Other stocks often have lower trading volumes and wider bid-ask spreads, making it difficult to execute trades efficiently and potentially leading to greater price volatility.
- Lack of Regulatory Oversight: Compared to major exchanges, the OTC Other tier has minimal regulatory requirements, offering less investor protection and potentially higher susceptibility to market manipulation.
- Price Volatility: Due to lower liquidity and less transparency, share prices can be more volatile and subject to significant fluctuations based on limited trading activity.
- Difficulty in Valuation: The scarcity of reliable and consistent financial reporting makes it challenging for investors to accurately value the company and assess its intrinsic worth.
- Verify any available financial statements directly from the company or third-party sources, even if unaudited.
- Research the company's management team and their track record through independent channels.
- Assess the company's business operations and market position through industry reports and news.
- Examine the trading volume and bid-ask spread to understand potential liquidity challenges.
- Investigate any news or regulatory filings from the company's primary listing (if any) or home country.
- Understand the company's capital structure and any outstanding debt obligations.
- Consult with a financial advisor experienced in OTC markets before making investment decisions.
- Established Operating History: Founded in 1987, Supermax has a long operational history as a manufacturer and distributor of medical products.
- Global Export Network: Exports to approximately 165 countries, indicating a legitimate and active international business presence.
- Tangible Products and Brands: Manufactures and markets physical products like medical gloves and contact lenses under recognized brands (Supermax, Aurelia, Maxter).
- Significant Employee Base: Employs 1624 individuals, suggesting a substantial and ongoing operational footprint.
- Diversified Business Activities: Engages in various activities beyond core manufacturing, including biomass energy and property holding, indicating a broader corporate structure.
SPMXF Healthcare Stock FAQ
What does Supermax Corporation Berhad do?
Supermax Corporation Berhad is a Malaysian investment holding company primarily focused on the manufacturing, distribution, and marketing of medical gloves and contact lenses. The company produces a wide array of natural rubber and nitrile latex gloves, along with personal protective equipment (PPE), serving critical needs in healthcare, laboratory, and pharmaceutical sectors. Operating under established brands such as Supermax, Aurelia, and Maxter, it sells its products to a diverse clientele including hospitals, doctors, pharmacists, and laboratories. Beyond manufacturing, Supermax is also involved in the trading and importing of latex gloves, the generation of biomass energy, and the marketing and distribution of other healthcare products and medical devices. Its extensive global reach includes exports to approximately 165 countries, encompassing major markets like the United States, the European Union, and Asia.
How does Supermax Corporation Berhad navigate the competitive landscape in the medical glove industry?
Supermax Corporation Berhad navigates the highly competitive medical glove industry through a multi-pronged strategy centered on global reach, brand diversification, and operational efficiency. The company leverages its extensive export network, reaching approximately 165 countries, to maintain a broad market presence and mitigate reliance on any single region. Its portfolio of established brands—Supermax, Aurelia, and Maxter—allows it to cater to different market segments and customer preferences, building brand loyalty among laboratories, hospitals, and medical professionals. Furthermore, by manufacturing both natural rubber and nitrile latex gloves, Supermax offers a comprehensive product range. While the industry faces challenges like price volatility and oversupply, the company's long operational history and diversification into contact lenses and other medical devices provide additional avenues for competitive differentiation and revenue stability.
What are the implications of Supermax Corporation Berhad's OTC 'Other' listing for investors?
Supermax Corporation Berhad's listing on the OTC "Other" tier carries several implications for investors, primarily concerning transparency, liquidity, and risk. The "OTC Other" tier has minimal disclosure requirements, and with an "Unknown" disclosure status for Supermax, investors may face significant challenges in accessing timely and comprehensive financial reports or material company updates. This lack of information can hinder accurate valuation and informed decision-making. Furthermore, stocks in this tier typically experience lower trading volumes and wider bid-ask spreads, leading to reduced liquidity. This means investors might find it difficult to buy or sell shares quickly without impacting the price, potentially incurring higher transaction costs. The limited regulatory oversight compared to major exchanges also means less investor protection, making thorough due diligence even more critical for potential investors.
What are the key factors to evaluate for SPMXF?
Supermax Corporation Berhad (SPMXF) holds an AI score of 54/100 (moderate). Not financial advice.
How frequently does SPMXF data refresh on this page?
SPMXF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven SPMXF's recent stock price performance?
Supermax Corporation Berhad (SPMXF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Extensive global distribution network covering approximately 165 countries. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SPMXF overvalued or undervalued right now?
Valuing Supermax Corporation Berhad (SPMXF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying SPMXF?
Before investing in Supermax Corporation Berhad (SPMXF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information regarding CEO's specific title, background, track record, and tenure was not provided in the source data and is marked as 'Unknown' or null.
- Competitor information (FMP PEER TICKERS) was not provided in the source data.
- Disclosure status for OTC market is 'Unknown' as per source data.